CO7160083A2 - Método de reducción de peso - Google Patents
Método de reducción de pesoInfo
- Publication number
- CO7160083A2 CO7160083A2 CO14279766A CO14279766A CO7160083A2 CO 7160083 A2 CO7160083 A2 CO 7160083A2 CO 14279766 A CO14279766 A CO 14279766A CO 14279766 A CO14279766 A CO 14279766A CO 7160083 A2 CO7160083 A2 CO 7160083A2
- Authority
- CO
- Colombia
- Prior art keywords
- dementia
- salt
- disease
- weight reduction
- reduction method
- Prior art date
Links
- 239000013585 weight reducing agent Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036631 Presenile dementia Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 206010048327 Supranuclear palsy Diseases 0.000 abstract 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Una sal de tipo camsilato de (1r,1R,4R)-4-metoxi-5- metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3Hdiespiro[ciclohexano-1,2-inden-12-imidazol]-4-amina, composiciones farmacéuticas que contienen la sal y usos terapéuticos de la sal para tratar patologías relacionadas con Aβ tales como la enfermedad de Alzheimer, síndrome de Down, angiopatía β-amiloide y afecciones tales como la demencia incluida la demencia de origen mixto vascular y degenerativo, demencia presenil, demencia senil y demencia asociada con la enfermedad de Parkinson, parálisis supranuclear progresiva o degeneración corticobasal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651335P | 2012-05-24 | 2012-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7160083A2 true CO7160083A2 (es) | 2015-01-15 |
Family
ID=49622926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14279766A CO7160083A2 (es) | 2012-05-24 | 2014-12-19 | Método de reducción de peso |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150174108A1 (es) |
| EP (1) | EP2854806A4 (es) |
| JP (1) | JP6438389B2 (es) |
| KR (1) | KR20150023404A (es) |
| CN (1) | CN104582701B (es) |
| AU (1) | AU2013202981B2 (es) |
| BR (1) | BR112014029302A2 (es) |
| CA (1) | CA2874512A1 (es) |
| CO (1) | CO7160083A2 (es) |
| HK (1) | HK1209041A1 (es) |
| MX (1) | MX2014014316A (es) |
| NZ (1) | NZ702666A (es) |
| RU (1) | RU2664442C2 (es) |
| SG (1) | SG11201407786XA (es) |
| WO (1) | WO2013173858A1 (es) |
| ZA (1) | ZA201408703B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579229A (en) | 2007-01-25 | 2011-07-29 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
| BR112014029308A2 (pt) * | 2012-05-24 | 2017-06-27 | Verva Pharmaceuticals Ltd | um método de melhorar a função hepática |
| US10039752B2 (en) * | 2016-07-21 | 2018-08-07 | Cipla Limited | Methazolamide for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2783241A (en) * | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| US6946243B2 (en) * | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| DE60110087T2 (de) * | 2000-08-11 | 2005-09-29 | Einar Stefansson | Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern |
| US20060159746A1 (en) * | 2003-03-18 | 2006-07-20 | Troup John P | Compositions comprising fatty acids and amino acids |
| PT2316456T (pt) * | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| EP1680131A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDOLE-O-GLUCOSIDES |
| WO2007114948A2 (en) * | 2006-04-04 | 2007-10-11 | The Brigham And Women's Hospital, Inc. | Methods and compositions for inhibiting cell death |
| NZ579229A (en) * | 2007-01-25 | 2011-07-29 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
| JPWO2011002011A1 (ja) * | 2009-07-01 | 2012-12-13 | キッセイ薬品工業株式会社 | Ｓｇｌｔ１阻害薬とｄｐｐ−ｉｖ阻害薬を組み合わせてなる医薬 |
| US20130143797A1 (en) * | 2010-06-25 | 2013-06-06 | Michael J. Tisdale | Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof |
| WO2012008549A1 (ja) * | 2010-07-15 | 2012-01-19 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112014029308A2 (pt) * | 2012-05-24 | 2017-06-27 | Verva Pharmaceuticals Ltd | um método de melhorar a função hepática |
-
2013
- 2013-03-15 WO PCT/AU2013/000259 patent/WO2013173858A1/en active Application Filing
- 2013-03-15 EP EP13794519.2A patent/EP2854806A4/en not_active Withdrawn
- 2013-03-15 CN CN201380033658.6A patent/CN104582701B/zh not_active Expired - Fee Related
- 2013-03-15 NZ NZ702666A patent/NZ702666A/en not_active IP Right Cessation
- 2013-03-15 AU AU2013202981A patent/AU2013202981B2/en not_active Ceased
- 2013-03-15 SG SG11201407786XA patent/SG11201407786XA/en unknown
- 2013-03-15 BR BR112014029302A patent/BR112014029302A2/pt not_active Application Discontinuation
- 2013-03-15 JP JP2015512967A patent/JP6438389B2/ja not_active Expired - Fee Related
- 2013-03-15 RU RU2014150946A patent/RU2664442C2/ru not_active IP Right Cessation
- 2013-03-15 CA CA2874512A patent/CA2874512A1/en not_active Abandoned
- 2013-03-15 KR KR20147035499A patent/KR20150023404A/ko not_active Application Discontinuation
- 2013-03-15 US US14/403,495 patent/US20150174108A1/en not_active Abandoned
- 2013-03-15 MX MX2014014316A patent/MX2014014316A/es unknown
-
2014
- 2014-11-26 ZA ZA2014/08703A patent/ZA201408703B/en unknown
- 2014-12-19 CO CO14279766A patent/CO7160083A2/es unknown
-
2015
- 2015-10-06 HK HK15109728.3A patent/HK1209041A1/xx unknown
-
2018
- 2018-02-09 US US15/892,989 patent/US20180333398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014014316A (es) | 2015-07-06 |
| JP2015520759A (ja) | 2015-07-23 |
| ZA201408703B (en) | 2018-07-25 |
| AU2013202981A1 (en) | 2013-12-12 |
| CN104582701A (zh) | 2015-04-29 |
| CN104582701B (zh) | 2018-01-16 |
| US20150174108A1 (en) | 2015-06-25 |
| WO2013173858A1 (en) | 2013-11-28 |
| RU2014150946A (ru) | 2016-07-10 |
| SG11201407786XA (en) | 2015-03-30 |
| JP6438389B2 (ja) | 2018-12-12 |
| US20180333398A1 (en) | 2018-11-22 |
| EP2854806A1 (en) | 2015-04-08 |
| RU2664442C2 (ru) | 2018-08-17 |
| HK1209041A1 (en) | 2016-03-24 |
| AU2013202981B2 (en) | 2014-11-13 |
| EP2854806A4 (en) | 2015-11-18 |
| BR112014029302A2 (pt) | 2017-06-27 |
| KR20150023404A (ko) | 2015-03-05 |
| NZ702666A (en) | 2016-08-26 |
| CA2874512A1 (en) | 2013-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091495A1 (es) | Sal de tipo camsilato | |
| BR112016013018A2 (pt) | Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf | |
| PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
| IN2014DN10386A (es) | ||
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| CO7160083A2 (es) | Método de reducción de peso | |
| CO7160082A2 (es) | Un método para mejorar la función hepática | |
| IL234616A0 (en) | A herbal preparation for the treatment of metabolic diseases | |
| IN2014KN00865A (es) | ||
| UA115079C2 (uk) | Сполуки як інгібітори діацилгліцеринацилтрансферази | |
| CU20130083A7 (es) | Compuestos y su uso como inhibidores de bace | |
| PH12015500755B1 (en) | A combination of adrenalin with an antidepressant for use in the treatment of shocks | |
| IN2013MU03838A (es) | ||
| BR112016004909A8 (pt) | compostos espirocíclicos como inibidores de triptofano hidroxilase, composição farmacêutica e seus usos | |
| BR112014010719A2 (pt) | moduladores não competitivos de receptor nicotínico | |
| WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |